文献速递泌尿系结石

血液检查在肾结石病代谢紊乱筛查中的效用

Utility of blood tests in screening for metabolic disorders in kidney stone disease.
PubMed 文献 · BJU Int · 2020-10-04

该研究前瞻性收集709例肾结石患者的临床和生化数据,分析血清钙、甲状旁腺激素、尿酸、氯、碳酸氢盐、钾和磷酸盐检测在筛查原发性甲状旁腺功能亢进、正常血钙性甲状旁腺功能亢进、高尿酸尿、远端肾小管酸中毒和高钙尿症中的效用。结论认为仅血清钙检测即可作为代谢筛查,额外血液检查不具成本效益,复发结石患者应进行24小时尿液全代谢评估。

要点

  • 血清钙升高见于2.3%患者,进一步检查诊断原发性甲状旁腺功能亢进在男性为0.2%、女性为4.6%。
  • 血清PTH升高无高钙血症者占15.1%,其中74.6%维生素D不足,无正常血钙性甲状旁腺功能亢进诊断。
  • 高尿酸尿占21.6%,高钙尿占47.1%,高尿酸血症与高尿酸尿无关,低磷血症与高钙尿无关。

核心结论

  • 肾结石患者应仅进行血清钙检测作为代谢筛查。
  • 额外血液检查筛查代谢紊乱不具成本效益,且可能提供虚假 reassurance。
  • 复发结石患者和高危患者应进行24小时尿液全代谢评估。

研究设计与样本

  • 前瞻性收集2011年4月至2017年2月期间在牛津大学医院NHS信托基金会就诊的709例肾结石患者的临床和生化数据。

主要发现

  • 血清钙升高见于2.3%患者。
  • 原发性甲状旁腺功能亢进诊断在男性为0.2%、女性为4.6%(基于血清钙记录者)。
  • 血清PTH升高无高钙血症者占15.1%,其中74.6%维生素D不足,无正常血钙性甲状旁腺功能亢进诊断。
  • 高尿酸尿占21.6%,高钙尿占47.1%。
  • 高尿酸血症与高尿酸尿无关,低磷血症与高钙尿无关。

临床怎么用

  • 对就诊的肾结石患者,仅检测血清钙进行代谢筛查。
  • 避免使用额外血液检查筛查代谢紊乱,因不具成本效益且可能误导。
  • 对复发结石患者和高危患者,进行24小时尿液收集的全代谢评估以识别可治疗的代谢异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the clinical utility of blood tests as a screening tool for metabolic abnormalities in patients with kidney stone disease. SUBJECTS AND METHODS: Clinical and biochemical data from 709 patients attending the Oxford University Hospitals NHS Foundation Trust for assessment and treatment of kidney stones were prospectively collected between April 2011 and February 2017. Data were analysed to determine the utility of serum calcium, parathyroid hormone (PTH), urate, chloride, bicarbonate, potassium and phosphate assays in screening for primary hyperparathyroidism, normocalcaemic hyperparathyroidism, hyperuricosuria, distal renal tubular acidosis (dRTA) and hypercalciuria. RESULTS: An elevated serum calcium level was detected in 2.3% of patients. Further investigations prompted by this finding resulted in a diagnosis of primary hyperparathyroidism in 0.2% of men and 4.6% of women for whom serum calcium was recorded. An elevated serum PTH level in the absence of hypercalcaemia was detected in 15.1% of patients. Of these patients, 74.6% were vitamin D-insufficient; no patients were diagnosed with normocalcaemic hyperparathyroidism. Hyperuricosuria was present in 21.6% of patients and hypercalciuria in 47.1%. Hyperuricaemia was not associated with hyperuricosuria, nor was hypophosphataemia associated with hypercalciuria. No patient was highlighted as being at risk of dRTA using serum chloride and bicarbonate as screening tests. CONCLUSION: This study indicates that individuals presenting with renal calculi should undergo metabolic screening with a serum calcium measurement alone. Use of additional blood tests to screen for metabolic disorders is not cost-effective and may provide false reassurance that metabolic abnormalities are not present. A full metabolic assessment with 24-h urine collection should be undertaken in recurrent stone formers and in those at high risk of future stone disease to identify potentially treatable metabolic abnormalities.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Eyre KS, Lewis F, Cui H, et al. Utility of blood tests in screening for metabolic disorders in kidney stone disease. BJU Int. 2020. PMID: 32967050. doi:10.1111/bju.15250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。